InSpark Technologies Announces the Results of the Home Use and Human Factors Study of Vigilant(TM) in People with Diabetes
11. Juni 2016 11:00 ET
|
InSpark Technologies
Vigilant met or exceeded all human factors criteria for safety, comprehension and ease of useEarly evidence of clinical benefit was demonstrated by a 51 percent reduction in the proportion of blood...